ASP1948
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ASP1948, covering 2024-11-01 to 2024-11-01. Get the full timeline:
Most recent: Clinical Trial Update: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors [Phase 1]